Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × olaparib × Other hematologic neoplasm × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 18 Breast 5 Genitourinary 3 Thoracic 2 Gastrointestinal 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 148 Cyclophosphamide 99 Daunorubicin 77 Methotrexate 73 Etoposide 63 Vincristine 56 Mercaptopurine 49 Dexamethasone 48 Rituximab 46 fludarabine 43 venetoclax 42 Doxorubicin 42 Azacitidine 42 Idarubicin 41 Imatinib Mesylate 38 Asparaginase 37 pegaspargase 34 Prednisone 34 Mitoxantrone 33 Radiotherapy 32 Thioguanine 31 Busulfan 28 fludarabine phosphate 23 Bendamustine Hydrochloride 23 nilotinib 21 Leucovorin 21 Filgrastim 21 obinutuzumab 20 ibrutinib 20 Peripheral Blood Stem Cell Transplantation 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03486873 2026-03-16

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡